Role of NMP22 bladder check test in early detection of bladder cancer with recurrence

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 5, 2010, Pages 1279-1282

  Kundal, Vijay K ^a   Pandith, Arshad A ^a   Hamid, Arif ^a   Shah, Azra ^a   Kundal, Rakhsha ^a   Wani, Saleem M ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bladder cancer; Cytology; Nuclear matrix protein(NMP); Transitional cell carcinoma

Indexed keywords

EID: 79955952456     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Berrios M, Osheroff N, Fisher PA (1985). In situ localization of topoisomerrase II, a major polypeptide component of the Drosophilia nuclear matrix fraction. Proc Natl Acad Sci U S A, 82, 4142-6.
2. Berezney R, Coffey DS (1974). Identification of a nuclear protein matrix. Biochem Biophys Res Commun, 60, 1410.
3. Farley J, Bray F, Pisani P, et al (2000). Cancer incidence; Mortality and prevalence worldwide IARC cancer Base no.5 Lyon, France; IARC Prass; 2001.
4. Fey EG, Krochmalnic GS, Penman (1986). The non-chromatin substructures of the nucleus: the ribonucleoprotein (RNP) containing and RNP-depleted matrices analysed by sequential fractionation and resinless section electron microscopy. J Cell Biol, 102, 1654.
5. Golin AL and Howard RS (1980). Asymptomatic microscopic haematuria. J Urol, 124, 389-91.
6. Gordan JN, Shu WP, Schlussel RN, et al (1993). Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res, 53, 4971-7.
7. Jemal A, Murray T, Ward E, et al (2005). Cancer statistics, 2005. CA Cancer J clin, 55, 10-30.
8. Johanson SL, Cohen SM (1997). Epidemiology and etiology of bladder cancer. Semim Snog Oncol, 13, 291-8.
9. Karakiewicz PI, Benavoun S, Zippe C, et al (2006). Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int, 97, 997-1001.
10. Keesee SK, Briggman JV, Thill G, et al (1996). Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr, 6, 189-214.
11. Khadra MH, Pickard RS, Charlton M, et al (2000). A prospective analysis of 1930 patients with haematuria to evaluate current diagnostic practice. J Urol, 163, 524-7.
12. Kumara-Siri MH, Shapiro LE, Surks MI (1986). Association of the 3,5 3e-triodo-L-thyronine nuclear receptor with the nuclear matrix of cultured growth horm one- producing rat pituitary tumor cells(GC cells). J Biol Chem, 261, 2844-52.
13. Landman J, Yongli C, Kavaler E, et al (1998). Sensitivity and specificity of NMP22, Telomerase and BTA in the detection of human bladder cancer. Urology, 52, 398-402.
14. Lee LW and Davis E Jr (1953). Goss urinary haemorrhage: a symptom, not a disease. JAMA, 153, 782-4.
15. Lynch CF, Cohen MB (1995). Urinary system. Cancer, 75, 316.
16. Miyanaga N, Akaza H, Ishikawa S, et al (1997). Clinical evaluation of nuclear matrix protein 22 in urine as a novel marker for urothelial cancer. Eur Urol, 31, 163-8.
17. Mohr DN, Offord KP, Owen RA, et al (1986). Asymptomatic microscopic hematuria and urologic disease:a population based study. JAMA, 256, 224-9.
18. Morrison AS (1984). Advances in the etiology of Urothelial Cancers. Urol Clin North Am, 11, 557-66.
19. Nakayasu H, Berezney R(1989). Mapping replicational sites in the eukaryotic nucleus. J Cell Biol, 108, 1-11.
20. Pardoll DM, Vogelstein B, Coffey DS (1980). A fixed site of DNA replication in eukaryotic cells. Cell, 19, 527-36.
21. Pashos CL, Botteman MF, Laskin BL, et al (2002). Bladder cancer: epidem iology, diagnosis and management. Cancer Pract, 10, 311-22.
22. Planz B, Jochims E, Deix T, et al (2005). The role of urinary cytology for detection of Bladder cancer. Eur J Surg Oncol, 31, 304-8.
23. Ries LAG, Eisner MP, et al (2000). SEER cancer statistics review, 1973-1997. Bestheda Md; National cancer Institute.
24. Sai YC, et al (1990). Allelic losses of chromosome 9, 11, 17 in human Bladder cancers. Cancer Res, 50, 44.
25. Soloway MS, Briggman JV, CarpintoGA, et al (1996). Use of a new tumor marker, urinary NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol, 156, 363-7.
26. Stamfer SD, Gennaro A, LanceWWillsey, et al (1998). Evaluation ofNMP22in the detection of TCC of bladder. J Urol, 159, 394-8.
27. Sultana SR, Goodman C M, Byrne D J, et al (1996). Microscopic hematuria: urological investigation using a standard protocol. Br J Urol, 78, 691-8.
28. Varkarakis MJ, Gaeta J, Moore RH, et al (1974). Superficial bladder tumor: aspects of clinical progression. Urology, 4, 414-20.
29. Young MJ and Soloway MS (1998). Office evaluation and management of bladder neoplasms. Urol Clin North Am, 25, 603-11.
30. Zheng W, MC Lanhlin JK, Gao YJ, et al (1992). Bladder cancer and occupation in Shanghai, 1980-1984. Am J Ind Med, 21, 877-85.
31. Zeitlin S, Parent A, Silverstein S, et al (1987). Pre-m RNA splicing and the nuclear matrix. Mol Cell Biol, 7, 111-20.